Last updated: February 20, 2026
What is the drug associated with NDC 00480-8725?
The National Drug Code (NDC) 00480-8725 corresponds to Ozempic (semaglutide) injection 0.5 mg. Ozempic is a glucagon-like peptide-1 (GLP-1) receptor agonist developed by Novo Nordisk. It is indicated primarily for type 2 diabetes management and has received expanding approval for weight management.
Market Overview
U.S. Market Size and Growth
- The U.S. diabetes treatment market reached approximately $60 billion in 2022.
- GLP-1 receptor agonists, including Ozempic, accounted for roughly 30% of the insulin and diabetes injectable market.
- The segment has experienced a compound annual growth rate (CAGR) of 12% over the past five years, driven by increasing diabetes prevalence and expanding labeling.
Indications and Off-label Uses
- Approved for Type 2 diabetes as an adjunct to diet and exercise.
- Recently approved for chronic weight management under the brand Wegovy (also semaglutide).
- Off-label use for obesity and prediabetes contributes to broader market potential.
Key Competitors
| Product |
Manufacturer |
Indication |
Price Range (per dose) |
| Trulicity (dulaglutide) |
Eli Lilly |
T2DM, weight management |
$7-$10 |
| Rybelsus (oral semaglutide) |
Novo Nordisk |
T2DM |
$10-$20 |
| Wegovy (semaglutide) |
Novo Nordisk |
Obesity, weight management |
$12-$14 |
| Byetta (exenatide) |
Eli Lilly |
T2DM |
$8-$12 |
Market Drivers
- Growing prevalence of obesity and T2DM.
- Ease of once-weekly dosing improves adherence.
- Insurance coverage expanding, though cost remains a barrier.
- Clinical evidence supporting weight-loss benefits broadens uses.
Regulatory Trends
- FDA approvals for obesity in adults in 2021.
- Medicare and private insurers increasingly offer coverage for GLP-1 therapies.
- Ongoing trials investigating cardiovascular benefits.
Price Analysis
Current Pricing Landscape (2023)
- Wholesale Acquisition Cost (WAC) for Ozempic 0.5 mg averages around $800 per 4-week supply (per dose).
- Market prices paid by insurers or patients are generally lower due to rebates and negotiations, estimated at around $600-$700.
- Similar drugs, like Trulicity, sell at comparable prices.
Cost Trends
- Prices for semaglutide products have stabilized since initial launch.
- Price reductions are unlikely unless generics or biosimilars enter the market.
- Novo Nordisk’s pricing strategy places its products in the premium segment but with insurance rebates expanding access.
Projections (Next 3-5 Years)
| Year |
Estimated Average Price (per 4-week supply) |
Key Notes |
| 2023 |
$600-$700 |
Stable, due to exclusivity and high demand |
| 2024 |
$610-$730 |
Slight increases consistent with inflation and demand |
| 2025 |
$620-$750 |
No significant generic competition expected |
| 2026 |
$620-$760 |
Potential discounts if biosimilars or generics are approved |
Assumptions: Price projections assume no major policy changes, biosimilar development, or shifts in insurance coverage. Pricing will remain stable unless biosimilars are approved or significant patent challenges occur.
Future Market and Price Dynamics
- Growth in obesity treatment may further expand sales.
- New formulations (e.g., higher doses or oral options) could influence pricing structures.
- Biosimilar entrants could target initial patent expirations, projected around 2030, potentially lowering prices.
Risks and Opportunities
Risks
- Patent litigation delays biosimilar entry.
- Regulatory or reimbursement hurdles could cap market expansion.
- Competitive launches could pressure prices.
Opportunities
- Increased adoption for weight management expands the user base.
- Generics or biosimilars could trigger price declines after patent expiry.
- International markets remain underpenetrated, offering expansion opportunities.
Key Takeaways
- The current drug priced at approximately $600-$700 per 4-week supply in the U.S.
- The market is growing at a CAGR of around 12% over the past five years.
- Market dynamics favor premium pricing with limited near-term competition.
- Biosimilars may emerge around 2030, potentially impacting prices.
- Market expansion into obesity and other indications will drive sales growth.
FAQs
1. What is the anticipated patent expiration for semaglutide branded products?
Patent protections are expected to expire around 2030, opening opportunities for biosimilar competition.
2. How does insurance coverage affect the retail price?
Insurance rebates and negotiated discounts typically reduce the out-of-pocket costs to patients, which can be substantially lower than WAC.
3. Are there biosimilar options currently available?
As of 2023, biosimilars for semaglutide are under development but not yet approved.
4. What factors influence the pricing stability of Ozempic?
Patents, manufacturing costs, demand, and insurance negotiations are primary factors.
5. What is the global market outlook for semaglutide?
Emerging economies show increasing demand driven by rising T2DM prevalence, though pricing pressures and regulatory hurdles vary.
References
[1] IQVIA. (2022). U.S. Diabetes Market Insights.
[2] FDA. (2023). Semaglutide (Ozempic) Label.
[3] EvaluatePharma. (2023). Global Diabetes Drug Market Reports.
[4] Novo Nordisk. (2023). Ozempic product information.
